Melittin based nano drug delivery system for cancer therapy
Main Article Content
Abstract
Melittin is a 26 amino acid polypeptide with a wide range of toxicological and pharmacological effect. It constitutes 40%-60% of dry honeybee (Apis melifera) venom. It has significant antitumor characteristics surface activity on cell lipid membranes, including potent hemolytic activity. It creates pores on the targeted cell membrane. Melittin has shown variety of anticancer effects in preclinical cell culture and animal model system. MEL has tremendous antifungal, antibacterial, anti-inflammatory and antitumor properties. Practical application of melittin in oncology is hampered by its strong, nonspecific hemolytic activity and intrinsic instability. To address these shortcomings, delivery systems are used to overcome the drawbacks of melittin and facilitate its safe delivery. To accomplish stable loading, side effect shielding, and tumor-targeted delivery, many nanocarrier systems—such as liposomes, cationic polymers, etc. have been created. To increase its toxic effect, carbon nanoparticles were used as carriers of melittin to breast cancer cells. Melittin complexed with nanographene oxide has a more harmful effect on breast cancer cells than melittin alone. Furthermore, nanodiamonds can shield cells from melittin's lytic effects. As a result of the findings, carbon nanoparticles as melittin carriers may find value in medicine in the future. PI3K/Akt and NF-kB signaling pathways are typically activated in P-gp-mediated MDR-related pathways, however melittin inhibits these processes. To overcome anticancer resistance and improve chemotherapy effectiveness, a polymersome based on a poly (lactic acid) (PLA)-hyaluronic acid (HA) di-block copolymer and encapsulating melittin and doxorubicin was created. By controlling P-gp overexpression pathways, a polymersome containing an anticancer medication and melittin might overcome.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Deng, Z.; Yan, F.; Jin, Q.; Li, F.; Wu, J.; Liu, X.; Zheng, H. (2014) Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome–microbubble complexes assisted by ultrasound. J. Control. Release, 174: 109–116
Hematyar M., Soleimani M., Es-Haghi A., Rezaei Mokarram A. (2018) Synergistic co-delivery of doxorubicin and melittin using functionalized magnetic nanoparticles for cancer treatment: Loading and in vitro release study by LC-MS/MS. Artif. Cells Nanomed. Biotechnol. 46: S1226–S1235.
Kurrikoff K, Aphkhazava D, Langel U. (2019) The future of peptides in cancer treatment. Curr Opin Pharmacol 47:27–32
Lee, M.-T., Sun, T.-L., Hung, W.-C. & Huang, H. W. (2013) Process of inducing pores in membranes by melittin. Proc. Natl Acad. Sci. USA 110: 14243–14248.
Soman N.R., Lanza G.M., Heuser J.M., Schlesinger P.H., Wickline S.A. (2008) Synthesis and Characterization of Stable Fluorocarbon Nanostructures as Drug Delivery Vehicles for Cytolytic Peptides. Nano Lett. 8:1131–1136.